Building on the Foundation of Four: Advancing Mitochondrial Targeted Geropeptide Medicine
Following the keynote lecture by Hazel H. Szeto on mitochondrial discovery and approved therapy, Targeting Mitochondria 2026 will continue the discussion with an industrial and entrepreneurial perspective on mitochondrial medicine.
We are pleased to welcome Kevin Slawin, M.D., Founder and CEO of Eos SENOLYTIX, USA, who will present a strategic lecture entitled: “Building on the Foundation of Four: Advancing Mitochondrial Targeted Geropeptide Medicine”
Eos SENOLYTIX is a longevity company developing MitoXcel™️ geropeptide technology for FDA-regulated clinical indications. The company’s platform is designed to address age-associated decline in mitochondrial membrane potential, a central feature of mitochondrial dysfunction linked to aging biology.
Through this approach, Eos SENOLYTIX is advancing mitochondrial-targeted geropeptide medicine within an IND-regulated FDA pathway, with an initial focus on sarcopenia and sarcopenic obesity.
Dr. Slawin will discuss how mitochondrial membrane potential, bioenergetics, and peptide-based technologies may open new directions for geroscience, healthy aging, and therapeutic development. His presentation will also address the broader challenge of translating mitochondrial discoveries into regulated clinical programs, industrial platforms, and future therapeutic applications.
Beyond Eos SENOLYTIX, Dr. Slawin is also Founder and CEO of Perseus SENOLYTIX, an oncology company developing mitochondrial-targeted oncopeptides as a potential new class of cancer therapeutics. He was previously co-founder of Bellicum Pharmaceuticals, Inc., which completed a $161 million IPO in December 2014.
He is also Founder, Chairman and CEO of PrintBio, Inc., a regenerative medicine company advancing 3D-printing technologies for surgical applications, and Founder and CEO of Miami Medicos, a membership organization connecting physicians, founders, executives, and investors within the healthcare innovation ecosystem.
This lecture will contribute to one of the central questions of Targeting Mitochondria 2026: How can mitochondrial science move from discovery to FDA-regulated development, industrial translation, and real therapeutic impact ?
